Opto Circuits gets US FDA nod for oximeter

Mediaid Inc., the US subsidiary of Bangalore-based Opto Circuits (I) Ltd. (OCI) has received an approval from the Food and Drug Administration (FDA) to market its SpO2 Sensor in the United States.

OCI acquired the patient monitoring division of Palco Labs, USA in January 2003 and renamed it Mediaid Inc.

SpO2 is an advanced non-invasive oximeter used to measure the level of oxygen saturation in the blood and pulse rate monitoring.

The Mediaid SpO2 is part of a revolutionary technology platform that improved the flexibility of the patient monitoring system in hospital emergency/operating rooms, to meet the ever-changing clinical needs of the dynamic healthcare environment.

Mediaid products use digital signal processing technology to calculate a patient's pulse rate and the functional saturation of arterial oxygen.

The annual worldwide demand for the product is estimated to be $0.5 billion of which 70 per cent is from the US market itself.

The FDA clearance opens immense business opportunity for OCI as their cost-efficient operations in India allows Mediaid SpO2 to be offered for sale in the competitive US market at a significantly lower price.